Fundamentals of Chemotherapy
Immunotherapy Administration
Hematologic most cancers (blood most cancers) - ANS-cancer that starts in bone marrow or
immune device cells.
-Ex: leukemia, lymphoma, multiple myeloma
Leukemia - ANScancer starts offevolved in blood-forming tissues like bone marrow
-causes plenty of ordinary blood cells to be produced and enter bloodstream
Lymphoma - ANS-cancer that starts in immune system (WBC=lymphocytes)
-hodgkin and non-hodgkins
-B lymphocytes (B cells) - make antibodies (micro organism and viruses, most common
lymphoma
-T lymphocytes (T cells) - boost/sluggish immune, damage germs and extraordinary cells
Hodgkin lymphoma - ANSReed-Sternberg cellular (cancer cells in conventional)
-typically starts in B cells
Non-Hodgkin's Lymphoma - ANS-big, various group of cancers in immune device cells
-indolent (gradual developing) or aggressive (rapid)
Myeloma - ANSCancer in plasma cells (WBC that produce antibodies)
Chemotherapy - ANSAll antineoplastic retailers used to treat most cancers, given thru oral and
parenteral routes or different routes as special in the trendy, now not consisting of hormonal
healing procedures.
Who can order chemotherapy? - ANSWritten and signed by using licensed unbiased
practitioners (MD/DO, PA, Oncology NP)
Can you use verbal orders for chemotherapy? - ANSNO! Only when conserving/preventing
admin.
Who can blend Chemotherapy? - ANSPharmacist, Pharmacy tech, MD/DO, qualified RN
Who can administer chemotherapy? - ANSRegistered Nurses with specialised schooling, prep
and schooling. See unique state legal guidelines and statutes
, How frequently is chemo competency reassessed> - ANSAnnual persevering with ed and
competency evaluation is suggested
What is the dose verification technique? - ANS-verify plan with affected person
-two practitioners confirm: drug name, dose, extent, rate, route, expiration date, look
-file verification in chart
What PPE is required for IV Chemotherapy? - ANS-Gloves: pairs, HD tested
-Gown: disposable, again closed, long sleeved
-Respirator: NIOSH authorized
-Eye & Face: face shield/mask
Neoadjuvant remedy (tumor burden) - ANSChemo BEFORE number one treatment
(commonplace in breast and colon)
Adjuvant remedy - ANSChemo AFTER number one treatment (not unusual in solid tumor)
Bone Marrow - ANSsoft, sponge-like tissue in middle of maximum bones, produce WBC, RBC,
and platelets.
Myelosuppression - ANSbone marrow activity is decreased, inflicting much less RBC, WBC and
Platelets.
Myeloablation - ANSsevere myelosuppression
Induction section - ANSinitial phase, commonly in hospital, supposed myelosuppression
Consolidation phase (intensification/postremission remedy) - ANSafter a success induction, kills
most cancers cells left in frame (ex radiation, stem cell transplant)
Synergy - ANSwhen one chemo drug allows some other work better on the equal time
Complete reaction - ANSno identifiable cancer gift for as a minimum one month or longer
Partial reaction - ANSMeasurable tumor reduced by using 50% for as a minimum one month
with out a new tumors
Stable disorder - ANSTumor length decreased by using less than 50% or less than 25%
increase in growth
Progressive disease - ANStumor increase greater than 25% or new cancer
What are the levels of the cell cycle? - ANS-G1 phase
-S section
Immunotherapy Administration
Hematologic most cancers (blood most cancers) - ANS-cancer that starts in bone marrow or
immune device cells.
-Ex: leukemia, lymphoma, multiple myeloma
Leukemia - ANScancer starts offevolved in blood-forming tissues like bone marrow
-causes plenty of ordinary blood cells to be produced and enter bloodstream
Lymphoma - ANS-cancer that starts in immune system (WBC=lymphocytes)
-hodgkin and non-hodgkins
-B lymphocytes (B cells) - make antibodies (micro organism and viruses, most common
lymphoma
-T lymphocytes (T cells) - boost/sluggish immune, damage germs and extraordinary cells
Hodgkin lymphoma - ANSReed-Sternberg cellular (cancer cells in conventional)
-typically starts in B cells
Non-Hodgkin's Lymphoma - ANS-big, various group of cancers in immune device cells
-indolent (gradual developing) or aggressive (rapid)
Myeloma - ANSCancer in plasma cells (WBC that produce antibodies)
Chemotherapy - ANSAll antineoplastic retailers used to treat most cancers, given thru oral and
parenteral routes or different routes as special in the trendy, now not consisting of hormonal
healing procedures.
Who can order chemotherapy? - ANSWritten and signed by using licensed unbiased
practitioners (MD/DO, PA, Oncology NP)
Can you use verbal orders for chemotherapy? - ANSNO! Only when conserving/preventing
admin.
Who can blend Chemotherapy? - ANSPharmacist, Pharmacy tech, MD/DO, qualified RN
Who can administer chemotherapy? - ANSRegistered Nurses with specialised schooling, prep
and schooling. See unique state legal guidelines and statutes
, How frequently is chemo competency reassessed> - ANSAnnual persevering with ed and
competency evaluation is suggested
What is the dose verification technique? - ANS-verify plan with affected person
-two practitioners confirm: drug name, dose, extent, rate, route, expiration date, look
-file verification in chart
What PPE is required for IV Chemotherapy? - ANS-Gloves: pairs, HD tested
-Gown: disposable, again closed, long sleeved
-Respirator: NIOSH authorized
-Eye & Face: face shield/mask
Neoadjuvant remedy (tumor burden) - ANSChemo BEFORE number one treatment
(commonplace in breast and colon)
Adjuvant remedy - ANSChemo AFTER number one treatment (not unusual in solid tumor)
Bone Marrow - ANSsoft, sponge-like tissue in middle of maximum bones, produce WBC, RBC,
and platelets.
Myelosuppression - ANSbone marrow activity is decreased, inflicting much less RBC, WBC and
Platelets.
Myeloablation - ANSsevere myelosuppression
Induction section - ANSinitial phase, commonly in hospital, supposed myelosuppression
Consolidation phase (intensification/postremission remedy) - ANSafter a success induction, kills
most cancers cells left in frame (ex radiation, stem cell transplant)
Synergy - ANSwhen one chemo drug allows some other work better on the equal time
Complete reaction - ANSno identifiable cancer gift for as a minimum one month or longer
Partial reaction - ANSMeasurable tumor reduced by using 50% for as a minimum one month
with out a new tumors
Stable disorder - ANSTumor length decreased by using less than 50% or less than 25%
increase in growth
Progressive disease - ANStumor increase greater than 25% or new cancer
What are the levels of the cell cycle? - ANS-G1 phase
-S section
